Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04641143 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder
A Phase 3 study, sponsored by Biohaven Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 456
- Enrollment target
NCT04641143: Completed Phase 3 study, sponsored by Biohaven Pharmaceuticals.
NCT04641143 is a Phase 3 study that has completed, run by Biohaven Pharmaceuticals. The registered enrollment target is 456 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (41% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04641143, a Phase 3 study, has completed, sponsored by Biohaven Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 456 participants
- Enrollment target
Study Summary
The study's purpose is to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in subjects with Obsessive Compulsive Disorder (OCD)
Primary Outcome
Improvement is measured by a lower total score
Interventions
- DRUG Placebo
- DRUG Troriluzole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 456 participants |
| Start Date | 2020-12-22 |
| Est. Completion | 2025-10-27 |
| Phase | Phase 3 |
What the finished NCT04641143 record still lists
NCT04641143 is an interventional study that assigns participants to a tested intervention. The registered 456 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (41% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04641143 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04641143 about?
NCT04641143 is a clinical study titled "Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder". The study's purpose is to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in subjects with Obsessive Compulsive Disorder (OCD)
What is the current status of trial NCT04641143?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 456 participants. The study started on 2020-12-22. Estimated completion is 2025-10-27.
What interventions are being tested in trial NCT04641143?
The interventions under investigation include: Placebo (DRUG), Troriluzole (DRUG).
Who is sponsoring clinical trial NCT04641143?
This trial is sponsored by Biohaven Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04641143's enrollment target sits among peer trials
456 827th of 2000 higher than 1,172 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04462302 · 456 participants · NA
An Internet-based Program to Help Cancer Survivors Manage Pain
- NCT05820919 · 456 participants · NA
Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase
- NCT06254612 · 456 participants · Phase 2
A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder
- NCT06457841 · 456 participants · NA
Stress and Resilience
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI